Havrix

Havrix is a vaccine that contains an inactivated hepatitis A virus and the adjuvant algeldrate, supplied as an injectable solution for intramuscular use. It is marketed in the European Union and prescribed by healthcare professionals to provide active immunity against hepatitis A infection. The product does not contain a defined numerical strength, and it is classified as a prescription‑only vaccine. Available for adults and children as recommended.

Havrix is indicated for the prevention of hepatitis A virus infection in individuals who are at risk of exposure.

- Routine immunization of infants, children, and adolescents according to national vaccination schedules. - Pre‑travel protection for persons traveling to regions with intermediate or high hepatitis A endemicity. - Immunization of laboratory workers handling hepatitis A virus specimens. - Post‑exposure prophylaxis for close contacts of confirmed hepatitis A cases when administered within two weeks of exposure. - Use in outbreak settings to quickly raise community immunity.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache or fatigue. - Nausea or mild gastrointestinal discomfort. - Transient muscle aches.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, or rash. - Guillain‑Barré syndrome, a rare neurological condition. - Persistent high fever lasting more than 48 hours. - Neurological symptoms such as weakness or numbness. - Any reaction requiring medical attention beyond routine care.

Healthcare providers should assess individual risk factors and medical history before administering Havrix.

- Do not administer to persons with a known severe allergy to any vaccine component, including algeldrate. - Postpone vaccination in individuals with moderate or severe acute illness until recovery. - Use caution in patients with a history of hypersensitivity reactions to other vaccines. - The safety of Havrix during pregnancy and lactation has not been established; discuss potential benefits and risks with a clinician. - Immunocompromised patients may have a reduced antibody response and should follow specific guidance. - Routine booster doses are not required for most healthy individuals after the primary series.

Havrix does not have many documented drug‑drug interactions, but certain substances may affect vaccine response or safety.

Avoid: - Concurrent administration of immunoglobulins or blood products that may interfere with the immune response to the vaccine. - Live viral vaccines given within four weeks before or after Havrix, as immune interference could occur.

Use with caution: - Immunosuppressive therapies (e.g., corticosteroids, chemotherapy) that may diminish antibody production; timing of vaccination may need adjustment. - Antipyretics such as acetaminophen or ibuprofen can be used to manage mild post‑vaccination symptoms but should not be taken prophylactically before injection. - Chronic medical conditions (e.g., liver disease) that increase hepatitis A risk may warrant earlier vaccination.